Morningstar

Checkpoint Therapeutics Inc CKPT

Morningstar Rating

Checkpoint Therapeutics Announces Cosibelimab Longer-Term Results in Advanced Cutaneous Squamous Cell Carcinoma Presented at ESMO Congress 2024

GlobeNewswire Sep 16, 2024 11:30am
Checkpoint Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference

GlobeNewswire Sep 4, 2024 12:00pm
Fortress Biotech Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights

GlobeNewswire Aug 13, 2024 8:05pm
Checkpoint Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Updates

GlobeNewswire Aug 12, 2024 12:30pm
Checkpoint Therapeutics Shares Rise After FDA Accepts Resubmission of Cosibelimab

Global News Select Jul 25, 2024 1:02pm
Checkpoint Therapeutics Announces FDA Acceptance of BLA Resubmission of Cosibelimab for the Treatment of Advanced Cutaneous Squamous Cell Carcinoma

GlobeNewswire Jul 25, 2024 11:30am
GC Cell and Checkpoint Therapeutics Advance Collaborative Cancer Research

GlobeNewswire Jul 15, 2024 12:00pm
Checkpoint Therapeutics Reaches BLA Alignment With FDA for Cosibelimab

Global News Select Jun 24, 2024 12:01pm
Checkpoint Therapeutics Shares Halved After FDA Complete Response Letter

Global News Select Dec 18, 2023 2:25pm
Checkpoint Therapeutics Gets FDA Response Letter on Cosibelimab Application

Global News Select Dec 18, 2023 12:44pm

Sponsor Center

Transparency is our policy. Learn how it impacts everything we do

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

How we make money

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your personal data

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

Verify your identity, personalize the content you receive, or create and administer your account.
Provide specific products and services to you, such as portfolio management or data aggregation.
Develop and improve features of our offerings.
Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

How we approach editorial content

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.

© Copyright 2024 Morningstar, Inc. All rights reserved. Dow Jones Industrial Average, S&P 500, Nasdaq, and Morningstar Index (Market Barometer) quotes are real-time.